Chinese e-commerce giant Alibaba Group Holding Ltd has scrapped plans to inject its pharmacy business into a Hong Kong-listed affiliate, citing regulatory uncertainties over the deal, as well as over China’s broader healthcare industry.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
